Key Highlights

  • Third-quarter Revenue was USD 102,884, down 66.1%.
  • Operating expenses fell 36.5% to USD 1.5 million.
  • Net loss was USD 31.6 million on a USD 30.4 million commitment fee.
  • Nine-month net loss was USD 38.7 million.

Onconetix, Inc. (NASDAQ:ONCO) reported third-quarter 2026 revenue of USD 102,884, down 66.1% from USD 303,651. Gross Profit was USD 78,166 versus USD 268,894, and the gross Margin fell to 76.0% from 88.6% because prior-year revenue consisted mainly of license revenue with minimal associated cost.

Total operating expenses fell 36.5% to USD 1,484,439 from USD 2,338,136, and the loss from operations narrowed 32.0% to USD 1,406,273. Selling, general and administrative expenses fell about USD 0.9 million on lower professional fees and legal costs.

Loss from operations was USD 1,406,273, and the gross margin reflects Cost of Goods Sold on a much smaller revenue base. The company recorded no income tax expense in either period.

Net Loss and the ELOC Commitment Fee

The net loss was USD 31,627,931 versus USD 8,783,702, which the filing attributes mainly to USD 30.4 million of commitment fee expense from a July 2026 Equity line of Credit purchase agreement. The prior-year quarter included about USD 5.4 million of loss on extinguishment of notes and USD 2.5 million of loss on issuance of preferred stock and warrants.

The loss per share was USD 76.01 versus USD 3,124.76, with figures adjusted for the company's share changes. The Earnings calendar listed no estimates for the quarter.

Cash was USD 2,741,657 versus USD 5,220,654 at year-end, and the company held a USD 2,500,000 note receivable. Total Assets were USD 15,545,227 versus USD 24,926,638, with Goodwill of USD 9,328,449 versus USD 18,549,005.

Accounts receivable were USD 103,421 versus USD 296,866, inventories were USD 192,644 versus USD 149,961, and total current assets were USD 5,937,415 versus USD 6,066,774.

Nine-Month Results and Operations

For nine months, revenue was USD 141,461 versus USD 511,775, down 72.4%, and gross profit was USD 80,814 versus USD 385,229. Operating expenses were USD 14,443,678 versus USD 16,960,718, and the loss from operations narrowed 13.3% to USD 14,362,864. The net loss was USD 38,710,109 versus USD 19,702,029, with a loss per share of USD 178.02.

The company is a commercial-stage biotechnology firm focused on oncology, and acquired Proteomedix AG, a Swiss company with the Proclarix diagnostic product, in December 2023. Research and Development expense in the quarter reflected a new clinical study agreement with LabCorp.

Derivative liabilities were USD 2,040,212 versus USD 6,985,347 and total liabilities were USD 4,035,219 versus USD 9,160,287. Series F redeemable preferred stock of 37,562 shares was carried at USD 28,798,350, and the accumulated Deficit was USD 169,924,667.

Accounts payable were USD 1,332,555 versus USD 1,757,695, accrued expenses were USD 531,406 versus USD 341,881 and total current liabilities were USD 4,029,405 versus USD 9,135,925. Common shares outstanding were 550,328 versus 3,117 at year-end, and additional paid-in Capital was USD 154,153,018.

Balance Sheet and Items to Follow

Total assets were USD 15,545,227 versus USD 24,926,638 at year-end 2025. Royalty revenues were de minimis in the quarter.

The filing describes the company as "a commercial stage biotechnology company". Items to follow include revenue from Proclarix, the effect of the equity line on share count and per-share results, and Operating Expense levels.